Predictive Biotech Revenue and Competitors

Predictive Biotech, Inc., a Salt Lake City, UT life sciences Company formed in 2015, is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive's four main placental-derived and Wharton's Jelly umbilical cord-derived products. Predictive Biotech products are regulated by the FDA under 21 CFR part 1271 section 361 as minimally manipulated allografts intended for homologous use. Predictive Technology Group, Inc., a Salt Lake City, UT therapeutics and life sciences company, is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through unique novel gene-based diagnostics, biotechnology treatments and companion therapeutics. Through its' wholly owned subsidiaries, Predictive Therapeutics, and Predictive Biotech, the company focuses on four main clinical categories: Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products. In addition to Predictive Biotech's efforts to advance regenerative medicine, Predictive Therapeutics is committed to assisting women in overcoming the devastating consequences of endometriosis via appropriate early-stage diagnosis and subsequent treatment.